EUVIMEDEUVIMED entdecken
Crossref

Treating Glabellar Lines With Botulinum Toxin: Does Your Patient Need to Frown Steadily?

Maurizio Cavallini, Roberto Dell'Avanzato, Salvatore Piero Fundarò, Fernando Urdiales-Gálvez, Marco Papagni, Gloria Trocchi, Mauro Raichi iD, Michela Zazzaron

Aesthetic Surgery Journal · 2024

DOI: 10.1093/asj/sjad349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Surgery Journal, 2024. Verfasst von Maurizio Cavallini und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The variable relationship between the orbicularis supercilii and frontalis muscles may cause side effects with botulin toxin; steadily frowning is the usual recommendation. Eliminating the need to frown until all injections are over might enhance efficacy and lessen the neurotoxicity risks related to muscle exhaustion.

Objectives

The goal of this study was to investigate whether the digital caliper–assessed distances between the medial and lateral corrugator injection sites and the midline differed significantly in patients persistently frowning from patients resting.

Methods

Seventy-six individuals with glabellar wrinkles treated with botulinum toxin in the authors’ private practices for glabellar lines voluntarily contributed their retrospective data about the positions of injection sites. The investigators had freely chosen to inject the medial and lateral sections of the corrugator supercilii during persistent maximum frown or at rest.

Results

The mean differences in distances between the medial and lateral injection points and the estimated midline were clinically trivial (1.0 ± 1.28 and 1.5 ± 2.53 mm, respectively), although the distances between the relaxed and contracted medial and lateral injection sites exceeded 1.8 and 2.5 mm in 33.9% and 46.4% of patients, respectively. Distance differences, not significant before 40 years old, were statistically significant only for the lateral injections in older patients (on average, 1.9 ± 3.01 mm).

Conclusions

The average distances from the medial and lateral injection points and the midline appear minimally different in patients who frown until all injections are over and, conversely, patients who rest. Persistently frowning might be advisable only in patients older than 40. Facial asymmetries may be a confounding factor. Level of Evidence: 4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ASkin AgingNeuromuscular AgentsHumansAgedAdultForeheadRetrospective StudiesFaceFacial Muscles

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

ORCID-Profile: Mauro Raichi

Zitieren

APA

Cavallini, M., Dell'Avanzato, R., Fundarò, S. P., Urdiales-Gálvez, F., Papagni, M., Trocchi, G., Raichi, M., & Zazzaron, M. (2024). Treating Glabellar Lines With Botulinum Toxin: Does Your Patient Need to Frown Steadily?. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjad349

Vancouver

Cavallini M, Dell'Avanzato R, Fundarò SP, Urdiales-Gálvez F, Papagni M, Trocchi G, et al. Treating Glabellar Lines With Botulinum Toxin: Does Your Patient Need to Frown Steadily?. Aesthetic Surgery Journal. 2024. doi:10.1093/asj/sjad349

BibTeX
@article{Cavallini2024,
  author = {Cavallini, Maurizio and Dell'Avanzato, Roberto and Fundarò, Salvatore Piero and Urdiales-Gálvez, Fernando and Papagni, Marco and Trocchi, Gloria and Raichi, Mauro and Zazzaron, Michela},
  title = {Treating Glabellar Lines With Botulinum Toxin: Does Your Patient Need to Frown Steadily?},
  journal = {Aesthetic Surgery Journal},
  year = {2024},
  doi = {10.1093/asj/sjad349}
}
Kostenlos starten →